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1. Introduction 
Diabetes mellitus is a serious chronic disorder of childhood and represents a major public 
health problem. Type 1 diabetes is the predominant form of diabetes during childhood and 
adolescence, accounting for about 90% of cases, although the growing epidemic of obesity 
has been associated with an increasing number of cases of childhood-onset type 2 diabetes 
(Craig et al., 2009; Patterson et al., 2009).  
The global incidence of type 1 diabetes is increasing worldwide, at an annual rate of 3-5%, 
particularly in children under the age of 5 years, and this trend leads to a significant health 
burden (Patterson et al., 2009). Recent studies have shown that in European countries 
childhood-onset type 1 diabetes is associated with three to four fold increased mortality 
when compared with the general population (Asao et al., 2003; Skrivarhaug et al., 2006). 
Similar data emerged from a long-term study of a young cohort with type 1 diabetes in the 
USA, where mortality was 7 times higher than in the non-diabetic population (Secrest et al., 
2010a). The high mortality reported for individuals with type 1 diabetes is mainly due to 
diabetes-related acute and chronic complications. As recently emerged from a large 
population-based cohort with long-standing childhood-onset type 1 diabetes, during the 
first decade of diabetes acute complications, such as diabetic ketoacidosis and 
hypoglycemia, are the main causes of death, being responsible for about 73% of cases, 
whereas during subsequent decades cardiovascular (CVD) and renal diseases become the 
main determinants of mortality (Secrest et al., 2010b).  
Diabetes vascular complications are divided in micro- and macrovascular disease. 
Microvascular complications include nephropathy (DN), retinopathy (DR) and neuropathy, 
whereas macrovascualar complications refer to cardiovascular, cerebrovascular and 
peripheral vascular disease (Marshall and Flyvbjerg, 2006). As a result of vascular 
complications, diabetes is the leading cause of blindness in working age people, is 
responsible for up to 40% cases of renal failure and is a major determinant of cardiovascular 
morbidity and mortality (Marshall and Flyvbjerg, 2006). 
2. Microvascular complications of type 1 diabetes 
Diabetic microvascular complications result from damage to the microvasculature of the 
kidney, retina and neurons and they generally progress throughout different stages.  
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2.1 Diabetic nephropathy 
2.1.1 Classification of diabetic nephropathy and structural kidney changes 
The changing occurring in the kidney in patients with type 1 diabetes are generally 
classified in five stages (Mogensen, 1999). The first stage is characterized by increases in 
glomerular filtration rate (GFR) and kidney hypertrophy. During the second phase subtle 
morphological changes occur together with progressive increases in urinary albumin 
excretion within the normal range. The third stage, also called incipient nephropathy, is 
characterized by the development of microalbuminuria, defined as an albumin excretion 
rate (AER) between 30-300 mg/24h or 20-200 µg/min, and by more profound structural 
changes. During the fourth phase there is a further increase in AER leading to 
macroalbuminuria (AER >200 µg/min or >300 mg/24h) and a consistent fall in GFR. 
Without any treatment this phase leads to the final stage of end stage renal disease (ESRD).  
Typical morphological changes occurring in the diabetic kidney are represented by diffuse 
glomerular basement membrane thickening, mesangial expansion, hyalinosis of the 
mesangium and arteriolar walls, broadening and effacement of podocyte foot processes, 
reduction in podocyte number, glomerulosclerosis and tubule-interstitial fibrosis (Osterby, 
1992). These morphological changes develop years before the clinical appearance of DN and 
this is an alarming aspect, given that when the disease is clinically evident some of the 
structural damage is already irreversible. 
Thickening of the basement membrane is a common bioptic finding related to DN and is 
associated with loss of glycosaminoglycans and associated negative charges, with consequent 
increased loss of anionic albumin (Fioretto and Mauer, 2007; Fioretto et al., 1994; Mauer and 
Najafian, 2006). A subsequent increase in the size of membrane pores leads to the development 
of non-selective proteinuria. An imbalance between the production and the degradation of 
mesangial matrix proteins, together with an increase in mesangial cells number, is responsible 
for mesangial expansion in DN (Fioretto and Mauer, 2007; Mauer and Najafian, 2006).  
 
Stage 1
 Hyperfiltration/hyperperfusion phase (often at diagnosis)
 Increased renal size
 AER: May be increased, but it becomes normal after starting insulin treatment
Stage 2
 Normoalbuminuria/Silent phase (2-5 years after diagnosis)
 Basement membrane thickening
 AER: Normal with transient increases related to poor glycemic control or exercise
Stage 3
 Microalbuminuria or incipient nephropathy phase (after 6-15 years)
 Further basement membrane thickening and mesangial expansion
 AER: 20-200µg/min or 30-300 mg/24h
Stage 4
 Overt diabetic nephropathy/Macroalbuminuria phase (after 15-25 years)
 Marked renal abnormalities, reduced renal function, increased blood pressure
 AER: >200 µg/min or >300 mg/24h
Stage 5
 End stage renal disease phase (after 25-30 years)
 Advanced glomerulopathy; marked decreased renal function, hypertension
 AER: Macroalbuminuria/ Often decreased due to glomerular occlusion
 
Fig. 1. Stages of diabetic nephropathy 
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Changes in the podocyte is another key feature of DN (Mauer and Najafian, 2006). 
Podocytes are highly specialised epithelial cells, interconnected by foot processes, which 
delimit the slit diaphragm, the main size-selective barrier in the glomerulus. The first 
detectable alteration in podocytes in the context of DN is a broadening and effacement of 
their foot processes (Kriz et al., 1998), which leads to a decrease in their density and number 
and a detachment from the glomerular basement membrane. The last phenomena are 
directly correlated to levels of albumin-creatinine ratio (ACR) and to the decline in GFR 
(Fioretto and Mauer, 2007). Podocytes can also undergo hypertrophy, apoptosis and 
increased synthesis of collagen IV, whereas there is a decreased synthesis of proteins, such 
as nephrin (Fioretto and Mauer, 2007).  
Another characteristic of DN is the hyalinosis of the afferent and efferent arterioles in the 
glomerulus, due to the accumulation of complement components, fibrinogen, 
immunoglobulins, albumin and other plasma proteins (Fioretto and Mauer, 2007). 
Hypertrophy and sclerosis of the iuxtaglomerular apparatus is another frequent finding in 
DN (Mauer and Najafian, 2006). 
2.1.2 Epidemiology of diabetic nepropathy 
DN affects about one third of people with type 1 diabetes after a disease duration of 20 
years and represents an important determinant of mortality (Jones et al., 2005). This has 
been recently confirmed in patients with both childhood-onset and adult-onset type 1 
diabetes (Groop et al., 2009; Orchard et al., 2010). In a large cohort of adults with type 1 
diabetes the presence of microalbuminuria, macroalbuminuria and ESRD was associated 
with 2.8, 9.2, and 18.3 times higher standardized mortality ratio, respectively (Groop et al., 
2009). Similarly, Orchard et al. reported a standardized mortality ratio of 6.4, 12.5 and 29.8 
for individuals with microalbuminuria, proteinuria and ESRD, respectively, in a cohort 
with childhood-onset type 1 diabetes followed longitudinally for 30 years (Orchard et al., 
2010).  
The natural history of DN has changed over the last decades and, whereas earlier landmark 
studies indicated that patients with microalbuminuria had a 60-85% risk of progressing to 
overt proteinuria within 6-14 years (Mogensen and Christensen, 1984; Parving et al., 1982; 
Viberti et al., 1982), more recent studies have reported a rate of progression of 30% over 10 
years, and an increasing number of cases of regression to normoalbuminuria (31 to 58%) (de 
Boer et al., 2011; Hovind et al., 2004; Perkins et al., 2003). Regression to normoalbuminuria 
has been associated with a better metabolic control, a better lipid and blood pressure profile 
as well as with non-modifiable risk factors, such as younger age and shorter duration of 
microalbuminuria (Hovind et al., 2004; Perkins et al., 2003). These data are encouraging and 
highlight the positive effect of improvements in treatment, particularly glycemic (1993) and 
blood pressure control (Lewis et al., 1993), in influencing the natural history of DN. 
However, this changing trend may be also related to an overestimation of the rate of 
progression in earlier studies.  
With regards to young people with childhood onset type 1 diabetes, recent studies from 
Sweden (Nordwall et al., 2004) and Australia (Mohsin et al., 2005) have shown a 
decreasing trend in DN. However, these positive results have not been consistently 
reported. In fact, data from Iceland (Tryggvason et al., 2005) and the UK (Amin et al., 
2009) indicated an unchanged trend in the incidence of microalbuminuria and DN over 
the last decades.  
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2.1.3 Early manifestations of diabetic nephropathy in youth with type 1 diabetes 
Microalbuminuria is the most common abnormal finding in children and adolescents with 
type 1 diabetes, whereas overt proteinuria is found in less than 1–1.5% of them (Jones et al., 
1998; Schultz et al., 1999b). Microalbuminuria often develops during puberty, whereas its 
prevalence during prepubertal years is rare (Janner et al., 1994; Lawson et al., 1996; 
Norgaard et al., 1989; Rudberg et al., 1993). The overall prevalence of microalbuminuria in 
youth with type 1 diabetes ranges between 4 and 26% (Bojestig et al., 1996; Cook and 
Daneman, 1990; Dahlquist and Rudberg, 1987; Joner et al., 1992; Jones et al., 1998; Mathiesen 
et al., 1986; Moore and Shield, 2000; Norgaard et al., 1989; Olsen et al., 2000; Rudberg et al., 
1993; Schultz et al., 1999b). This large variation in the prevalence of microalbuminuria is due 
to differences in study design, duration of diabetes, age range, and glycemic control. Most 
studies investigating microalbuminuria have been cross-sectional and clinic based, with 
only a few being longitudinal, but mainly with a retrospective design. Jones et al. (Jones et 
al., 1998) reported a prevalence of 14.5% during 8.5 years of diabetes duration, whereas 
Rudberg et al. (Rudberg et al., 1993) reported a prevalence of 24% after 15 years diabetes 
duration. The most recent data from the Oxford Regional Prospective Study (ORPS), a 
population-based inception cohort of children with type 1 diabetes, has shown a cumulative 
prevalence of microalbuminuria of 25.7% after 10 years and of 50.7% after 19 years of 
diabetes duration (Amin et al., 2008). 
After puberty, rates of rise in albumin excretion tend to decline and, longitudinal studies 
suggest that microalbuminuria is persistent in only 50% of adolescents; whereas in the other 
40-50% urinary albumin excretion returns into the normal range after 3-10 years from the 
onset of microalbuminuria (Amin et al., 2008; Gorman et al., 1999). However, with longer 
follow-up cases of transient or intermittent microalbuminuria may become persistent. In 
addition, although urinary albumin excretion may return into the normal range, the renal 
morphological changes associated with microalbuminuria can persist and increase the risk 
of its recurrence and progression (Steinke and Mauer, 2008). Few data are available on the 
rate of progression of microalbuminuria to macroalbuminuria in young people with type 1 
diabetes. The ORPS has shown a progression rate of around 13% after 3.2 years from the 
onset of microalbuminuria, a rate similar to that reported in adults (Amin et al., 2008). 
Another renal abnormality often detected in youth with type 1 diabetes is increased GFR 
(Amin et al., 2005; Rudberg et al., 1992). Hyperfiltration, which has been associated with 
increased renal size often precedes the onset of microalbuminuria (Amin et al., 2005; 
Rudberg et al., 1992). In some, although not all studies, increased GFR has emerged as an 
independent predictor of microalbuminuria, and a recent meta-analysis has reported a 2.7 
increased risk of developing microalbuminuria associated with hyperfiltration (Magee et al., 
2009).  
2.2 Diabetic retinopathy 
2.2.1 Classification and structural changes 
DR begins with the appearance of non-proliferative retinal abnormalities, which then progress 
to sight-threatening proliferative lesions (Aiello et al., 1998; Williams and Pickup, 2004) . The 
early stage of DR is characterised by the development of capillary microaneuryms, which 
consist in small blind outgrowths of retinal capillaries developing in areas where the wall is 
weakened (Aiello et al., 1998; D'Amico, 1994; Williams and Pickup, 2004). As the retinal 
damage progresses, there is the appearance of non-proliferative abnormalities, including 
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hemorrhages, exudates and the development of vascular obstruction, intraretinal 
microvascular abnormalities, and infarction of the retinal nerve fibers causing cotton wool 
spots (Aiello et al., 1998; D'Amico, 1994; Williams and Pickup, 2004). Although this stage is not 
sight-threatening, it is highly predictive of progression to more advanced stages of 
retinopathy. Proliferative retinopathy is characterized by the development of new vessels, 
secondary to ischemia, on the surface of the retina and/or the optic disc (Aiello et al., 1998; 
D'Amico, 1994; Williams and Pickup, 2004). These new vessels can bleed into the vitroretinal 
space, and cause visual loss. In addition, the subsequent formation of fibrous tissue can cause 
tractional retinal detachment (Williams and Pickup, 2004). This stage is associated with a high 
risk for visual impairment related to hemorrhages and retinal detachment. 
Diabetic macular oedema can complicate both non-proliferative and proliferative 
retinopathy and is a serious cause of vision loss in patients with diabetes (Ciulla et al., 2003). 
It is characterized by increased microvascular permeability and deposition of hard retinal 
exudates (Ciulla et al., 2003). This stage involves the breakdown of the blood-retinal barrier, 
with leakage of plasma from small blood vessels in the macula. Swelling of the macula is 
then followed by deposition of hard retinal exudates as a consequence of deposition of 
lipids and lipoproteins following plasma re-absorption (Ciulla et al., 2003).  
 
Proposed disease severity level Dilated ophthalmoscopy findings 
No apparent retinopathy No abnormalities 
Mild nonproliferative DR Microaneurysms only 
Moderate nonproliferative DR 
More than just microaneurysms, but less than 
severe nonproliferative DR 
Severe nonproliferative DR 
No signs of proliferative DR, with any of the  
following: 
- More than 20 intraretinal hemorrhages in 
each of four quadrants 
- Definite venous beading in two or more 
quadrants  
- Prominent intaretinal microvascular 
anomalies in one or more quadrants 
Proliferative DR 
One or more of  the following: 
- Neovascularization 
- Vitreous or preretinal hemorrhage 
Table 1. International clinical DR disease severity scale 
Retinal damage in diabetes is mainly due to leakage of retinal blood vessels and inadequate 
retinal perfusion (Aiello et al., 1998; D'Amico, 1994; Williams and Pickup, 2004). It has been 
suggested that one of the initial alterations in the retinal hemodynamic is represented by 
retinal vasodilatation and hyperperfusion, due to hypoxia and increased release of nitric 
oxide (Joussen et al., 2004). This is followed by an impairment of the retinal vascular 
autoregulation with increased tension in the epithelial wall and increased vascular 
permeability, which, in turn, cause vascular leakage and aneurysm formation (Kohner et al., 
1995; Scherrer et al., 1994). 
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Early structural abnormalities in the retinal microvasculature are characterised by 
thickening of the basement membrane, loss of endothelial cells and pericytes and increased 
capillary permeability (Kohner et al., 1995). An important characteristic of retinopathy is the 
loss of pericytes from the retinal capillaries (D'Amico, 1994; Feng et al., 2007; Frank, 2004). 
Pericytes are contractile cells which have an important role in the regulation of the capillary 
blood flow and their loss has been associated with the development of retinal 
microaneurysms (Feng et al., 2007; Kuwabara and Cogan, 1963). The loss of pericytes, 
associated with that of capillary endothelial cells, contributes to the disruption of the 
integrity of the blood–retinal barrier. Thickening of the capillary basement membrane and 
deposition of extracellular matrix components are additional mechanisms contributing to 
the alterations in the retinal blood flow (Feng et al., 2007).  
Retinal leukostasis has been also associated with DR and, in particular, with capillary 
occlusion and the consequent appearance of retinal areas of non perfusion (Aiello et al., 
1998; D'Amico, 1994; Williams and Pickup, 2004). These alterations contribute, in turn, to 
retinal ischemia, which is a potent stimulus for vascular neoformation (Miyamoto and 
Ogura, 1999).   
2.2.2 Epidemiology of retinopathy 
DR is the leading cause of blindness in people of working age in Western countries (Ciulla et 
al., 2003). The prevalence of DR increases with age and its was approximately 17.7 per 100 
people with diabetes in the year 2005 (Deshpande et al., 2008). DR can be diagnosed already 
after 5 years from the onset of diabetes, and almost all patients will show variable degrees of 
DR after 20 years diabetes duration.  
Recent data from the Wisconsin Epidemiologic Study of DR have shown that the 25-year 
cumulative incidence of visual impairment in adults with type 1 diabetes was 13% and that 
of severe visual impairment was 3%. Patients with onset of diabetes during more recent 
years have a lower prevalence of visual impairment when compared with those diagnosed 
in the past, independently of duration of diabetes (Klein et al., 2010). This is in agreement 
with some other recent studies reporting a declining incidence of retinopathy and other 
microvascular complications (Nathan et al., 2009; Nordwall et al., 2004).  
2.2.3 Early manifestations of retinopathy in youth with type 1 diabetes 
Early stages of DR can be detected in young people with type 1 diabetes, as shown by a 
population based study from Australia, where early background retinopathy was detected 
in 24% of the study population after 6-year diabetes duration (Donaghue et al., 2005). 
Similarly, in a Swedish study retinopathy was detected in 27% of young patients after 13 
years of duration (Nordwall et al., 2006). Children with type 1 diabetes under the age of 10 
years are at minimal risk of DR, but the prevalence rate increases after 5 years from 
diagnosis in post-pubertal patients (Klein et al., 1984). In an incident cohort, early 
retinopathy was detected in 12% of prepubertal children compared to 29% of adolescents, 
after 6 year type 1 diabetes duration (Donaghue et al., 2005). Interestingly, adolescents with 
type 1 diabetes have a higher risk of progression to sight-threatening DR when compared to 
adults and the progression may be particularly rapid when glycemic control is poor 
(Maguire et al., 2005). As for DN, cases of regression have also been reported for DR 
(Maguire et al., 2005).  
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2.3 Diabetic neuropathy 
Diabetic neuropathy is the most common neuropathy in industrialized countries, and it is 
associated with a wide range of clinical manifestations (Tesfaye et al., 2010). Diabetic 
neuropathy is defined as a clinical or subclinical disorder, without any additional causes other 
than diabetes, and can be either somatic or autonomic (Boulton et al., 2005). Early diagnosis 
and treatment of diabetic neuropathy are important given that peripheral neuropathy is 
associated with a high risk of feet injury in patients with type 1 diabetes (Boulton et al., 2005). 
In addition, diabetic autonomic neuropathy can lead to a significantly increased morbidity and 
mortality, mainly when involves the cardiovascular system (Boulton et al., 2005). 
2.3.1 Classification and epidemiological data of diabetic neuropathy 
Chronic distal symmetric polyneuropathy (DPN) is the most common form of diabetic 
neuropathy and affects 30-50% of patients with type 1 diabetes  and can be asymptomatic in 
up to 50% of them (Tesfaye et al., 2010). DPN implies symmetric damage of peripheral small 
sensory and large motor nerve fibres. It generally starts from the most distal end of the feet 
and then extend proximally over time and can lead to foot ulceration and amputation of 
lower limbs (Boulton et al., 2005). Dysfunction of peripheral small nerve fibres is 
characterised by parasthesiae, burning, and deep aching pain. If larger nerve fibres are 
affected, vibration, light touch and joint position senses are impaired, and tendon reflexes 
are absent (Boulton et al., 2005). Less common forms of diabetic somatic neuropathy include 
focal or multifocal neuropathies, which are characterized by entrapment of a peripheral 
nerve commonly the median, ulnar or peroneal nerve (Boulton et al., 2005).  
Diabetic autonomic neuropathy is a disorder of the autonomic nervous system in the context 
of diabetes and can affect the cardiovascular, gastrointestinal, urogenital systems and the 
sudomotor function (Tesfaye et al., 2010). Autonomic neuropathy can be observed in around 
20% of asymptomatic patients with diabetes (Tesfaye et al., 2010). Clinical symptoms of 
autonomic neuropathy do not generally occur until long after the onset of diabetes. Subclinical 
autonomic dysfunction can, however, occur within two years of diagnosis in patients with type 
1 diabetes (Boulton et al., 2005). Dysautonomic features may reflect the involvement of 
different systems and manifest as postural hypotension and orthostatic lightheadedness, 
gastroparesis, gastric fullness, early satiety, sexual dysfunction, bladder dysfunction, gustatory 
sweating or anhidrosis and pupillomotor dysfunction (Boulton et al., 2005). 
 
Peripheral neuropathies 
Generalized symmetric polyneuropathies 
- Acute sensory 
- Chronic sensorimotor 
- Autonomic 
Focal and multifocal neuropathies 
- Cranial 
- Truncal 
- Focal limb 
- Proximal motor  
Autonomic neuropathy 
- Cardiovascular: Postural hypotension, 
resting tachicardia, exercise intolerance 
- Genitourinary: Bladder dysfunction, 
Erectile dysfunction 
- Gastrointestinal: Gastric paresis, 
constipation/diarrhea, fecal 
inconinence 
- Sudomotor: Gustatory sweating, 
Anhidrosis, Heat intolerance, Dry skin 
- Metabolic: hypoglycemia unawareness 
- Pupillomotor dysfunction 
Table 2. Neuropathies in diabetes 
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Diabetic neuropathy is characterized by a reduction in the number of fibers, degeneration of 
the myelin sheath as well as changes affecting the endoneurial connective tissue, vessels and 
perineurium (Greene et al., 1992). The process of nerve demyelination may progress to 
Wallerian degeneration, in which the nerve axon is also injured and the distal part of the 
axon dies (Greene et al., 1992). 
2.3.2 Early signs of diabetic neuropathy in youth with type 1 diabetes 
In the most comprehensive epidemiological studies involving both adult and pediatric 
patients, DPN was detected in 9 to 58% of the study populations (Boulton et al., 2005). Data on 
autonomic neuropathy indicate a prevalence ranging from 14% to 75%, with a high number of 
youth with type 1 diabetes presenting suclinical signs of autonomic dysfunction, even after a 
short duration of T1D. This variability across different studies is mainly related to differences 
in the characteristics of the study cohorts as well as to the use of different testing modalities 
and different criteria and cut off values (Trotta et al., 2004; Verrotti et al., 2009).  
3. Macrovascular complications of type 1 diabetes 
Patients with type 1 diabetes have an increased risk of developing cardiovascular disease 
(CVD) relative to the nondiabetic population, and premature atherosclerosis represents the 
main cause of morbidity and mortality in type 1 diabetes populations (Laing et al., 2003).  
There is extensive evidence in support of the concept that atherosclerosis begins early in life 
(Ross, 1993) and therefore identification of CVD risk factors and preventive strategies 
should be started during childhood and adolescence (Dahl-Jorgensen et al., 2005). Children 
and adolescents with type 1 diabetes represent a high risk population with regards to CVD, 
given that cardiovascular risk factors are common among them (Dahl-Jorgensen et al., 2005; 
Margeirsdottir et al., 2008; van Vliet et al.) and they can contribute to their poor long-term 
prognosis (Skrivarhaug et al., 2006). A recent study has shown that as many as 86% of youth 
with type 1 diabetes has at least one, 45% at least two and 15% at least three CVD risk 
factors, including high HbA1c, high blood pressure, dyslipidemia, smoking and family 
history of CVD events (Margeirsdottir et al., 2008). These data are alarming given that it is 
well known that CVD risk factors can persist or track over time (Berenson, 2002) and 
therefore contribute to the overall burden associated with type 1 diabetes.   
3.1 Early signs of macrovascular disease in youth with type 1 diabetes 
The early stages of the atherosclerotic process are silent, but autopsy studies have detected 
early structural alterations in the arteries of youth, where they have been associated with the 
same risk factors than in adults (Berenson et al., 1998). The earliest recognizable pathologic 
intimal lesions are the fatty streaks, which make their appearance in the aorta of children 
even before 3 years of age (McGill et al., 2000; Williams et al., 2002). Fatty streaks represent 
an early manifestation of lipid accumulation in the vessel wall and they have been 
associated with increased cholesterol levels as well as with hyperglycemia (McGill et al., 
2000).  
Technology progresses over the last years have made possible to look for early surrogate 
markers of atherosclerotic vascular disease. These markers are represented by structural 
alterations such as increased intima-media thickness as well as functional changes 
represented by decreased flow-mediated dilatation and increased arterial stiffness, as 
detected by pulse wave velocity (Dahl-Jorgensen et al., 2005).  
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Several studies have consistently shown that children and adolescents with type 1 diabetes 
present signs of endothelial dysfunction, as measured by flow-mediated dilation in the 
brachial artery (Jarvisalo et al., 2004; Singh et al., 2003).  In addition, increased  aortic and 
carotid intima-media thickness has been reported in children with type 1 diabetes (Harrington 
et al., 2010; Jarvisalo et al., 2001). Besides, markers of inflammation and oxidative stress are 
significantly increased in youth with type 1 diabetes when compared with age-matched 
controls and they can mediate vascular damage (Snell-Bergeon et al., 2010). 
Progression of CVD in youth with type 1 diabetes can be more aggressive than in adults 
with diabetes, therefore highlighting the importance of early preventive strategies (Dahl-
Jorgensen et al., 2005). 
 
Early manifestations of CVD in youth with type 1 diabetes 
 Increased inflammatory markers 
 Increased oxidative stress 
 Increased intima-media thickness 
 Decreased flow-mediated dilatation 
 Increased pulse wave velocity 
Table 3. Early manifestations of CVD in youth with type 1 diabetes 
4. Pathogenesis of micro- and macrovascular complications 
Vascular complications in the context of diabetes are the result of an interplay between 
hemodynamic and metabolic factors and the consequent activation of common intermediate 
pathways, associated with increased synthesis and release of growth factors, cytokines, 
chemokines and oxidant species, which are all final mediators of vascular damage (Cooper, 
2001). 
A strong association exists between the presence of micro- and macrovascular complications in 
people with type 1 diabetes (Girach and Vignati, 2006). In particular, it is well known that DN 
is a key risk factor for cardiovascular complications and many patients with renal impairment 
die of CVD-related causes even before developing ESRD (Groop et al., 2009). In addition, there 
is growing evidence suggesting that increases in albumin excretion, even within the normal 
range, in the general population as well as in people with type 1 diabetes, represents a 
determinant of CVD (Klausen et al., 2004). The link between micro- and macrovascular disease 
could be represented by endothelial dysfunction, as an underlining feature of both processes, 
as well as by a certain degree of inflammation, which has been associated to the presence of 
both micro- and macrovascular complications (Schalkwijk and Stehouwer, 2005).  
4.1 Glycemic control 
Chronic hyperglycemia is known to activate several deleterious pathways implicated in the 
damage of vessels: protein glycation, increased glucose flux through alternative polyol and 
hexosamine pathways, increased oxidative stress, which then stimulate secondary 
intracellular signaling pathways leading to production of growth factors, cytokines and 
inflammatory factors (Brownlee, 2001).  
Several epidemiological studies have shown a direct and strong association between long-
term glycemic control, as expressed by HbA1c levels, and the risk of developing 
nephropathy, retinopathy and neuropathy (Amin et al., 2008; Danne et al., 1998; Gallego et 
al., 2008; Nordwall et al., 2009). In addition, HbA1c has been shown to be a key determinant 
also of early signs of atherosclerosis (McGill et al., 1995).  
www.intechopen.com



























Fig. 2. Risk factors for the development of vascular complications in adolescents with type 1 
diabetes 
The Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes 
Interventions and Complications (EDIC) studies have clearly shown the beneficial effect of 
strict glycemic control in reducing the risk of microvascular and macrovascular complications 
in subjects with type 1 diabetes (1993; 2003). In the adolescent cohort of the DCCT, a positive 
effect of improved glycemic control on complication risk was obtained. Intensive insulin 
therapy reduced the risk for the development and progression of DR by 76% and 54%; the 
occurrence of microalbuminuria and proteinuria by 39% and 54% and that of clinical 
neuropathy by 60% when compared to the conventional treated group (1994). Data from the 
DCCT/EDIC study also showed that intensive insulin therapy reduced the risk for any 
cardiovascular disease by 42% and of nonfatal myocardial infarction, stroke or death from 
CVD cause by 57% (Nathan et al., 2005). The beneficial effect of intensive insulin treatment in 
patients with childhood-onset type 1 diabetes also emerged from the Oslo study, where long-
term glycemic control predicted coronary atherosclerosis (Larsen et al., 2002).  
In addition, the EDIC study raised the important concept of ‘metabolic memory’; in other 
words although after the end of the DCCT HbA1c levels became comparable between the 
intensively and conventionally treated groups, patients belonging to the first group still kept 
an advantage from prior better HbA1c levels (2003). Therefore, the EDIC data highlighted 
the need of implementing intensive management as soon as type 1 diabetes is diagnosed. 
This was further supported by recent data related to DR, showing that, although at year 10 
of the EDIC there was still a decrease in DR progression risk in the intensively treated adult 
group, in the adolescent cohort retinopathy progression at year 10 of the EDIC did not differ 
between the previous DCCT intensively and conventionally treated groups, thus indicating 
loss of the metabolic memory (White et al., 2010). Interestingly, 79% of the difference in the 
metabolic effect between adults and adolescents after 10 years from the end of the DCCT 
was due to the difference in mean HbA1c levels during the DCCT between the two cohorts. 
This 1% difference, which did not seem to play a major role during the DCCT and early 
EDIC years with regards to the outcomes, seems to be a major player in the long run (White 
et al., 2010).  
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4.2 Blood pressure and plasma lipids 
Elevated blood pressure and alterations in its circadian rhythm are common findings in 
people with type 1 diabetes and have been associated with the risk of developing vascular 
complications (Gallego et al., 2008; Marcovecchio et al., 2009b; Tesfaye et al., 1996). Increases 
in blood pressure have been found to precede or occur concomitant with the appearance of 
microalbuminuria in adolescents with type 1 diabetes (Marcovecchio et al., 2009b; Schultz et 
al., 2001). Similarly, higher than normal systolic and diastolic blood pressure independently 
contribute to the development of DR (Gallego et al., 2008). Blood pressure has been also 
associated with early markers of atherosclerosis (Dahl-Jorgensen et al., 2005). 
Lipid abnormalities have also been linked to the development and progression of micro- 
and macrovascular complications in adolescents with diabetes (Dahl-Jorgensen et al., 2005; 
Kordonouri et al., 1996; Marcovecchio et al., 2009a).  
4.3 Duration and age at onset of type 1 diabetes 
Duration of diabetes is another major determinant of complication risk. Although vascular 
complications rarely appear before puberty, prepubertal duration of diabetes is an 
important determinant for their development (Coonrod et al., 1993; Orchard et al., 1990). 
Patients with type 1 diabetes from early childhood and especially those diagnosed under 
five years of age seem to have slightly delayed onset of persistent microalbuminuria during 
the first 10 to 15 years duration compared with patients diagnosed later in childhood or 
during puberty. However, this initial protective effect of a younger age at diagnosis 
disappears over time (Amin et al., 2008; Donaghue et al., 2003). After 15 years of diabetes 
duration the risk of developing microalbuminuria is similar between subjects diagnosed 
with diabetes before 5 years of age when compared with those diagnosed between 5-11 
years of age or after the age of 11 years, suggesting that age at the onset of diabetes does not 
influence the overall risk for microalbuminuria (Amin et al., 2008). A recent study has 
highlighted that also for DR, although patients diagnosed at a young age have a longer time 
free of proliferative retinopathy, this advantage then gradually disappears and youth 
diagnosed before the age of 15 years have a higher risk of proliferative retinopathy when 
compared with those diagnosed when aged 15-40 years (Hietala et al., 2010). 
4.4 Puberty  
Puberty is an important factor implicated in the development and progression of vascular 
complications. Poor glycemic control is a common finding among adolescents with type 1 
diabetes (1994; Holl et al., 2003). In addition, puberty is associated with a decrease in insulin 
sensitivity, and adolescents with type 1 diabetes are more insulin resistant when compared 
with healthy controls (Dunger, 1992). Rapid growth, hormonal and metabolic changes 
characterise this period of life and can influence complications risk (Dunger, 1992).  
4.5 Gender 
A gender dimorphism has been reported for vascular complications. In particular, during 
adolescence the risk for microalbuminuria is higher in female than in male subjects with 
comparable glycemic control (Amin et al., 2008; Jones et al., 1998), whereas among adults 
with type 1 diabetes the risk is higher for males  (Hovind et al., 2004). These differences have 
been related to variations in the hormonal milieu and to a higher degree of insulin resistance 
in girls (Schultz et al., 1999a).  
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4.6 Other factors 
Genetic factors represent another important contributing factor for the development of 
vascular complications, as suggested by their familial clustering, and by the observation that 
only a subset of patients with poor glycemic control develop severe long-term complications 
(1997). Family history of cardiovascular risk factors is associated with increased risk of 
microvascular complications in the offspring (Monti et al., 2007; Seaquist et al., 1989). 
A high body mass index (BMI) represents another potential risk factor for microvascular 
complications in youth with type 1 diabetes (Stone et al., 2006). In addition, obesity is a well-
known risk factor for cardiovascular disease (Dahl-Jorgensen et al., 2005). 
Environmental factors, including diet and lifestyle, can also contribute to the risk of 
developing vascular complications. Smoking in people with type 1 diabetes has been 
associated with an increased risk of developing vascular complications (Chase et al., 1991; 
Mohamed et al., 2007).  
5. Management of microvascular and macrovascular complications 
5.1 Screening 
Diabetic microvascular and macrovascular complications are often asymptomatic during 
their early stages, and once symptoms develop, they may be difficult to reverse. Therefore, 
longitudinal repeated screening for vascular complications initiated during early 
adolescence is currently recommended  
The American Diabetes Association (ADA) recommends to start screening in patients with 
type 1 diabetes aged 10 years or older after a disease duration of 3-5 years, with yearly 
follow-up (Silverstein et al., 2005). The International Society for Pediatric and Adolescent 
Diabetes (ISPAD) recommends screening from the age of 11 years in those with 2 year 
diabetes duration and from 9 years in those with a 5 year duration for both nephropathy 
and retinopathy (Donaghue et al., 2007). Measurement of urinary albumin excretion is the 
basis for early detection of microalbuminuria and can be achieved with: 1) 24-hour urine 
collection; 2) overnight timed urine collections; 3) albumin-creatinine ratio (ACR) or 
albumin concentration on a early morning spot urinary sample (Donaghue et al., 2007). 24-
hour or timed urine collections are often difficult to collect in children and adolescents. 
Assessing ACR in early morning urines is the easiest method to carry out in an office setting 
and it generally provides accurate information (Donaghue et al., 2007).  
With regards to DR, several techniques can be used, including direct and indirect 
ophthalmoscopy, stereoscopic digital and color film based fundus photography, mydriatic 
or nonmydriatic digital color or monochromatic single-field photography. The best 
technique to identify and grade retinopathy is represented by retinal photography, through 
dilated pupils, but dilated indirect ophtalmoscopy associated with biomicroscopy is an 
acceptable alternative (Ciulla et al., 2003).  
In contrast to well-established criteria for when starting screening for DN and DR, it is unclear 
when to commence screening for neuropathy. History and physical examination are generally 
the recommended methods of screening (Donaghue et al., 2007). Clinical examination, 
including history of pain, paresthesia, numbness and physical examination of ankle reflexes 
and vibration and light touch sensation, is a fundamental part of screening, although not being 
as sensitive or specific as nerve conduction studies (Donaghue et al., 2007). Autonomic 
neuropathy can be assessed with specific autonomic nerve tests, such as heart rate response to 
deep breathing, standing from a lying position, Valsalva maneuver, heart rate variations at 
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rest, QT interval, postural changes in BP and pupil responses to light and dark adaptation 
(Donaghue et al., 2007). These tests need to be carefully standardized and therefore they are 
largely used as screening methods for complications at a population level. 
Additional screening concerns risk factors for CVD, such as dyslipidemia and hypertension. 
Blood lipids should be checked soon after diagnosis and if normal then repeated after 5 
years (Donaghue et al., 2007). Office blood pressure should be assessed annually and in case 
of abnormal values, hypertension needs to be confirmed by ambulatory blood pressure 
monitoring. 
 
When to start 
 Microvascular complications: at age 11 with 2 year duration of 
type 1 diabetes or from age 9 with 5 year duration (for 
nephropathy and retinopathy; unclear for neuropathy) 
 Macrovascular complications: after 12 years 
Screening Method:  
1) Diabetic nephropathy 
 Annual albumin-creatinine ratio in a spot urine sample or first 
morning albumin concentration 
2) Diabetic retinopathy 
 Annual dilated fundus ophthalmoscopy or fundal photography  
3) Diabetic neuropathy 
 History and physical examination 
 Nerve conduction and autonomic tests 
4) Macrovascular disease  
 Annual assessments of blood pressure 
 Assessment of lipid levels every 5 years 
Table 4. Screening for micro- and macrovascular complications in youth with type 1 diabetes 
5.2 Interventions 
Improving glycemic control is the cornerstone of treatment strategies aiming at reducing the 
development and progression of microvascular and macrovascular complications. The 
DCCT and EDIC study clearly showed the importance of a strict glycemic control both in 
adults and in adolescents with type 1 diabetes (1994). The importance of keeping HbA1c 
within targets has also been highlighted by other studies, but similarly to the DCCT, 
subsequent studies have confirmed the difficulties encountered when dealing with young 
people with type 1 diabetes (Holl et al., 2003; Petitti et al., 2009). Tight glycemic control in 
the DCCT and subsequent studies was associated with a higher risk of complications, such 
as hypoglycemia and weight gain (1994). In addition, poor compliance is an important issue 
to be taken into account in adolescents with type 1 diabetes. Furthermore, other factors 
besides insulin therapy are relevant for metabolic control, such as dietary habits, education, 
family interactions, cultural and psychological aspects (Holl et al., 2003), and therefore they 
need to be taken into account in order to define a successful treatment plan. 
Treatment with angiotensin converting enzyme inhibitors (ACEIs) is recommended when 
hypertension is confirmed (Donaghue et al., 2007). ACEIs are treatment of choice in adults 
with microalbuminuria, based on evidence that their use decrease the rate of progression 
and even increase rates of regression of microalbuminuria (Lewis et al., 1993). A beneficial 
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effect of anti-hypertensive treatment, and in particular of treatment with ACEIs, has also 
been demonstrated for DR (Chaturvedi et al., 1998). The EURODIAB Controlled Trial of 
Lisinopril in type 1 diabetes showed a significant effect of lisinopril in reducing by around 
50% the progression of retinopathy in normotensive and normo- or microalbuminuric 
patients (Chaturvedi et al., 1998). However, there is no universal recommendation for the 
use of ACEIs in children and adolescents with microalbuminuria. The ADA recommends to 
start treatment with ACEIs in presence of persistent microalbuminuria (Silverstein et al., 
2005). Similarly, the recent ISPAD guidelines suggest to use ACEIs or angiotensin receptor 
blockers in presence of persistent microalbuminuria, in order to prevent progression to 
proteinuria (Donaghue et al., 2007), even though the lack of evidence in this context is 
acknowledged.  
Dyslipidemia should be managed firstly with improvements in glycemic control and dietary 
changes and, in case of persistence of high cholesterol levels, treatment with statins should 
be considered, although there is no enough evidence of their use in children apart from 
those with familial hypercholesterolemia  (Donaghue et al., 2007). However, in adults statins 
have been shown to be effective in the primary and secondary prevention of major 
cardiovascular events  (2002). 
Adolescents with type 1 diabetes need to be persuaded to avoid smoking. In addition, it is of 
paramount importance also to avoid increases in BMI, given that adiposity is a well known 
risk factor for cardiovascular complications, and in some studies it has also been associated 
with microvascular complications of type 1 diabetes (Donaghue et al., 2007).  
 
Targets to reduce diabetic vascular complications 
 HbA1c: ≤7.5% (without severe hypoglycemia) 
 LDL cholesterol: <2.6mmol/l 
 HDL cholesterol: >1.1mmol/l 
 Triglycerides: <1.7mmol/l 
 Blood pressure: <90th percentile for age, sex and height 
 BMI <95th centile  
 Avoid smoking 
 Physical activity: moderate: >1hr/day 
 Sedentary activities: <2hr/day 
 Healthy diet 
Table 5. Recommendations to reduce diabetic vascular complications (ISPAD guideline 
2006-2007) 
New potential therapeutic possibilities for the treatment of vascular complications are 
emerging and they include drugs targeting specific pathways implicated in their 
pathogenesis. These include inhibitors of aldose reductase, inhibitors of protein kinase C, 
antagonists of advanced glycation end-products, glycosaminoglycans, inhibitors of growth 
factors and anti-oxidants (Soro-Paavonen and Forbes, 2006). Up to now, there are no 
definitive data to recommend the use of these new potential therapies but the overall 
objective of targeting specific metabolic and hemodynamic pathways implicated in the 
pathogenesis of diabetic vascular complications could lead to validation of these classes of 
drugs and discovery of novel pharmaceuticals. 
www.intechopen.com
Microvascular and Macrovascular  




The risk for micro- and macrovascular complications is high in young patients with 
childhood-onset type 1 diabetes and their development negatively influence their long-term 
prognosis. 
Early identification of risk factors and prevention of diabetes complications are of 
paramount importance in children and adolescents. Diabetic vascular complications are 
often asymptomatic during their early stages, and once symptoms develop, it can be 
difficult to reverse them. Therefore, screening for vascular complications started during 
early adolescence, as currently recommended, is essential. Identification of risk factors and 
subclinical signs of complications is of paramount importance for the early implementation 
of preventive and therapeutic strategies, which could change the course of vascular 
complications and improve the prognosis of youth with diabetes. Efforts should be made for 
optimizing glycemic control, to keep blood pressure and lipid levels within target levels, to 
avoid smoking, promote exercise and a healthy diet. Future studies are required to test the 
efficacy and safety of new therapies, which could target specific metabolic or hemodynamic 
pathways implicated in the pathogenesis of diabetic complications. 
Further advances in genomics, proteomics and in other ‘omics’ and the integration of the 
findings of these different sciences will hopefully allow a better understanding of the 
pathogenesis of diabetic vascular complications in the near future and will potentially lead 
to a personalized medicine for young patients with diabetes 
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